Ask AI
Back Back
ProCE Banner Activity

Personalizing Bispecific Antibody Therapy in Multiple Myeloma

Clinical Thought

Bispecific antibodies have rapidly transformed from promising investigational therapies into foundational components of multiple myeloma management. As their use expands across the disease continuum, thoughtful patient selection, individualized sequencing, and proactive supportive care have become just as important as choosing the appropriate therapeutic target. In this commentary, experts summarize key insights from a symposium at EHA 2026, discussing the evolving role of bispecific antibodies in multiple myeloma, the future treatment landscape, and the ongoing challenges of optimizing their use in clinical practice.

Released: July 28, 2026

Continue Activity View Activity

Share

Faculty

Ja Min Byun

Ja Min Byun, MD, PhD

Associate Professor
Department of Internal Medicine
Seoul National University College of Medicine
Seoul National University Hospital
Seoul, Korea
Jens Hillengass

Jens Hillengass, MD, PhD

Professor of Oncology and Vice Chair of Research
Department of Medicine
Roswell Park Cancer Institute
Professor of Internal Medicine
University of Buffalo
Buffalo, New York
Philippe Moreau

Philippe Moreau, MD

Professor of Clinical Hematology
University Hospital Hotel-Dieu
Nantes, France
Katja C. Weisel

Katja C. Weisel, MD

Professor and Leading Physician
University Medical Center Hamburg-Eppendorf
Deputy Director of II. Medical Clinic and Polyclinic
Department of Oncology, Hematology, BMT with Department of Pneumology
Co-Director of University Cancer Center Hamburg
Hamburg, Germany

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This activity has been designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals who care for patients with multiple myeloma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate emerging safety and efficacy data on new bispecific antibody therapies into the personalized treatment of patients with multiple myeloma 

  • Identify patients with multiple myeloma who may be eligible for ongoing clinical trials evaluating currently available and emerging bispecific antibodies

  • Manage and mitigate adverse events associated with bispecific antibody treatment in patients with multiple myeloma

  • Compare safety and efficacy profiles among available bispecific antibodies to individualize therapy selection for patients with relapsed/refractory multiple myeloma

Financial Disclosures

Primary Author

Ja Min Byun, MD, PhD, has no relevant financial relationships to disclose.

Jens Hillengass, MD, PhD: consultant/advisor/speaker: Bristol Myers Squibb, Johnson & Johnson, Pfizer, Siemens; researcher: Bristol Myers Squibb, GSK.

Philippe Moreau, MD, has no relevant financial relationships to disclose.

Katja C. Weisel, MD: researcher: AbbVie, Amgen, BeiGene, Bristol Myers Squibb, GSK, Janssen, Sanofi; consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, BeiGene, Bristol Myers Squibb, CellCentric, GSK, Janssen, Karyopharm, Novartis, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi, Stemline, Takeda.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for data analysis or summarization influencing content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.